Opinion on Pharmaceuticals in North America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Abbott: Humira sales forecast increased

With Abbott's Humira (adalimumab) being reimbursed by 95% of managed care organizations three months after its US launch, the company has re-forecast the product's 2003 results. Abbott is under pressure to build US share rapidly, before the expected 2005 launch of Celltech/Pharmacia/Pfizer's rival rheumatoid arthritis drug CD870.

Published By Datamonitor
16 Apr 2003
CommentWire
CommentWire

Abbott: meta-analysis is good news for psoriasis drug but approval remains a hurdle

A new article in the Journal of the American Medical Association reveals that interleukin-12/23 inhibitors such as Abbott's Ozespa do not raise cardiovascular risks in psoriasis patients compared to placebo or TNF inhibitors. Abbott will welcome the news, but Datamonitor believes that while Ozespa is a key contender if resubmitted for approval, hurdles remain as more extensive data are needed.

Published By Datamonitor
24 Aug 2011
CommentWire
CommentWire

Abbott: Reductil suspension represents another nail in the coffin for obesity drugs

Following a regulatory recommendation, Abbott Laboratories has suspended sales of its controversial obesity drug Reductil in Europe (branded elsewhere as Meridia and Sibutrex). Meanwhile, the FDA has called for new contraindications to be added to the drug's label following data from the SCOUT trial. These issues highlight the commercial risks inherent in targeting the burgeoning obesity market.

Published By Datamonitor
22 Jan 2010
CommentWire
CommentWire

Abbott: safeguarding market leadership through elagolix deal

Global healthcare firm Abbott has boosted its gonadotropin releasing hormones pipeline through a deal with Neurocrine for the continued development of new promising candidate elagolix. The partnership is favorable for both parties, with Abbott seeking to maintain its endometriosis market leadership after Lupron's patent expiry in 2014.

Published By Datamonitor
17 Jun 2010
CommentWire
CommentWire

Abgenix/Amgen: colon cancer drug could challenge Erbitux

Abgenix and Amgen plan to submit an application to market colon cancer drug panitumumab by the end of 2005 after US regulators awarded the drug fast track status. With this indication already dominated by Genentech's Avastin and ImClone's Erbitux, panitumumab will need to demonstrate a survival advantage in phase III testing in order to establish itself in the colon cancer drug market.

Published By Datamonitor
03 Aug 2005
CommentWire
CommentWire

Acadia: a novel insomnia treatment is stirring

Results from a recent clinical trial have demonstrated that Acadia's ACP-103 improves quality of sleep by increasing slow wave sleep. This suggests that ACP-103 has potential as a novel treatment for sleep maintenance insomnia. However, more trials with larger patient samples are needed and the drug candidate has many hurdles to overcome before it can claim a place in the crowded insomnia market.

Published By Datamonitor
21 Apr 2006
CommentWire
CommentWire

Acorda/Biogen Idec: pricing will determine success of symptomatic MS therapy

The FDA has approved Acorda's Ampyra for the symptomatic treatment of multiple sclerosis, making it the first therapeutic option approved to address walking impairments experienced by patients with the disease. However, despite favorable efficacy data, prescriptions are likely to be limited by price concerns and the risk of seizures.

Published By Datamonitor
27 Jan 2010
Expert View
Expert View

ACR 2009: Benlysta outshines disappointing rheumatoid arthritis data

Datamonitor recently attended this year's American College of Rheumatology Annual Conference in Philadelphia. No ground-breaking data for rheumatoid arthritis therapies were presented; instead, systemic lupus erythematosus stole the limelight. Human Genome Sciences' Benlysta in particular generated a stir, being the first drug in this indication to generate positive data at Phase III.

Published By Datamonitor
23 Oct 2009
CommentWire
CommentWire

Actelion/GlaxoSmithKline: future of innovative orexin drug class in doubt

Actelion and GlaxoSmithKline have discontinued development of their Phase III insomnia candidate, almorexant, following a review of clinical data. The drug, an orexin receptor antagonist, had been widely regarded by leading sleep disorder specialists as an innovative and promising insomnia treatment. Termination of the drug's development casts doubt over the future of the drug class.

Published By Datamonitor
28 Jan 2011
Expert View
Expert View

Acute coronary syndrome: GRAVITAS gives AstraZeneca and Eli Lilly a mandate, but who will cash in?

Results from the GRAVITAS trial suggest that there is no benefit in treating low-risk post-percutaneous coronary intervention patients with high residual platelet activity with a double dose of clopidogrel. The results are not definitive, however: it was a relatively small trial performed in relatively low-risk patients, and may have been insufficiently powered.

Published By Datamonitor
29 Nov 2010

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.